Joerg Heyer

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index4.4kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(16), Genetic factors in colorectal cancer(12), Lung Cancer Treatments and Mutations(8), Cancer Cells and Metastasis(6), Monoclonal and Polyclonal Antibodies Research(6)

Publications47 total

Supplementary Figure 1, Table 1 from <i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor Model
2023Open Access
Supplementary Figure 1, Table 1 from <i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor Model
2023Open Access
Data from <i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor Model
2023Open Access
Data from <i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor Model
2023Open Access
Abstract 379: Genomic profiling of the tumors harboring activating epidermal growth factor receptor mutations
Cancer Research·2017
Clinical Application of a Cancer Genomic Profiling Assay to Guide Precision Medicine Decisions
Personalized Medicine·2017· 29 citedOpen Access
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
Genome Medicine·2016· 73 citedOpen Access
Large-scale genomic sequencing of colorectal cancer in the Japanese population.
Journal of Clinical Oncology·2016
Clinical next generation sequencing in lung cancer: Beyond personalized medicine.
Journal of Clinical Oncology·2016
Additional file 1: Figure S1. of Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
Figshare·2016Open Access
Spontaneous Genomic Alterations in a Chimeric Model of Colorectal Cancer Enable Metastasis and Guide Effective Combinatorial Therapy
PLoS ONE·2014· 14 citedOpen Access
Abstract 2737: Spontaneous genomic alterations identified in a chimeric model of colorectal cancer guide effective combinatorial therapy.
Cancer Research·2013
Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R
Cancer Research·2011
Abstract 1727: Preclinical evaluation of pan-VEGFR inhibitor tivozanib in combination with capecitabine, sirolimus or erlotinib in genetically engineered tumor models support combinations based on complementary mechanisms
Cancer Research·2011· 1 cited
Abstract 642: Novel EGFR inhibitory antibodies directed against EGFR mutants with potentially reduced toxicity
Cancer Research·2011
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations
Genes & Cancer·2011· 34 citedOpen Access
Abstract P1-03-06: Population Based In Vivo Biomarker Discovery Using Engineered Human Tumors
Cancer Research·2010
Non-germline genetically engineered mouse models for translational cancer research
Nature reviews. Cancer·2010· 179 citedOpen Access
Abstract 1378: Preclinical efficacy of the triple VEGFR inhibitor tivozanib (AV-951) in chimeric breast and lung tumor models
Cancer Research·2010
Abstract 3267: Human population based engineered breast tumor model for in vivo biomarker discovery
Cancer Research·2010
page 1 of 3Next →

Frequent Co-authors

Murray O. Robinson(20), Yinghui Zhou(13), William M. Rideout(11), Angela Bressel(11), M. Isabel Chiu(10), Sireesha Yalavarthi(10), Tong Zi(9), Karuppiah Kannan(8), Raju Kucherlapati(7), Ruojie Wang(7), Jie Lin(7), Raju Kucherlapati(6), Martin Lipkin(6), Kan Yang(6), Meaghan Russell(6), Ruobai Sun(6), Alexei Protopopov(6), Stephen Lyle(6), James Watters(6), Marie Lia(5)